Sugi Predict

Sugi Predict / Compounds / SCHEMBL211116

SCHEMBL211116

SCHEMBL211116

CCOC(=O)c1cc(C(C)=O)on1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.55
▸ CYP1A2 P05177 1/20 0.47
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ACR P10323 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21523627 0.87 MAPT (0.53) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL892609 0.86 HCAR2 (0.55) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL14996437 0.86 MAPT (0.52) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL31124057 0.86 MAPT (0.49) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL3821807 0.85 MAPT (0.54) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL1535177 0.82 MAPT (0.49) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL31124076 0.81 MAPT (0.48) MAPTCYP1A2MEN1KMT2ATSHR
SCHEMBL434805 0.80 MEN1 (0.61) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL31286841 0.79 CYP1A2 (0.50) MAPTCYP1A2MEN1KMT2ANPC1
SCHEMBL162619 0.79 CYP1A2 (0.50) MAPTCYP1A2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 — — EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 — — US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 — — EP disclosed
CN-112566636-A Compound and use thereof 优曼尼蒂治疗公司 2021-03-26 — — CN disclosed
EP-3784234-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2021-03-03 — — EP disclosed
US-10919885-B2 Compounds and uses thereof YUMANITY THERAPEUTICS, INC. (US) 2021-02-16 — — US disclosed
US-10919885-B2 Compounds and uses thereof YUMANITY THERAPEUTICS, INC. (US) 2021-02-16 — — US disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 — — US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 — — US disclosed
WO-2004043458-A1 BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2004-05-27 — — WO disclosed
US-20040092521-A1 Bicyclic-substituted amines as histamine-3 receptor ligands ABBOTT LABORATORIES 2004-05-13 — — US disclosed
EP-0191045-B1 USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES ZAMBON S.p.A. (IT) 1989-12-20 — — EP disclosed
EP-0190298-B1 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF ZAMBON S.p.A. (IT) 1989-10-18 — — EP disclosed
US-4766137-A 4-(isoxazolyl)-thiazole-2-oxamic acids and derivatives thereof ZAMBON S.P.A. (IT) 1988-08-23 — — US disclosed
US-4766138-A Use of 4-(isoxazolyl)-thiazole-2-oxamic acid derivatives ZAMBON S.P.A. (IT) 1988-08-23 — — US disclosed
EP-0191045-A1 USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES. ZAMBON SPA (IT) 1986-08-20 — — EP disclosed
EP-0190298-A1 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF. ZAMBON SPA (IT) 1986-08-13 — — EP disclosed
WO-1986000900-A1 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF ZAMBON, S.P.A. (IT) 1986-02-13 — — WO disclosed
WO-1986000899-A1 USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES ZAMBON S.P.A. (IT) 1986-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919885-B2 Compounds and uses thereof NLN, ACHE, CLN6 MAPT 22/4885CYP1A2 1091/4885MEN1 1807/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885CYP1A2 316/4885MEN1 1934/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885CYP1A2 316/4885MEN1 1934/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885CYP1A2 316/4885MEN1 1934/4885
US-20040092521-A1 Bicyclic-substituted amines as histamine-3 receptor ligands HRH3, HRH4, HRH1 MAPT 3414/4885CYP1A2 1015/4885MEN1 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.